{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:09:59Z","timestamp":1777604999317,"version":"3.51.4"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alpha-synuclein (aSyn) is a central player in the pathogenesis of synucleinopathies due to its accumulation in typical protein aggregates in the brain. However, it is still unclear how it contributes to neurodegeneration. Type-2 diabetes mellitus is a risk factor for Parkinson\u2019s disease (PD). Interestingly, a common molecular alteration among these disorders is the age-associated increase in protein glycation. We hypothesized that glycation-induced neuronal dysfunction is a contributing factor in synucleinopathies. Here, we dissected the impact of methylglyoxal (MGO, a glycating agent) in mice overexpressing aSyn in the brain. We found that MGO-glycation potentiates motor, cognitive, olfactory, and colonic dysfunction in aSyn transgenic (Thy1-aSyn) mice that received a single dose of MGO via intracerebroventricular injection. aSyn accumulates in the midbrain, striatum, and prefrontal cortex, and protein glycation is increased in the cerebellum and midbrain. SWATH mass spectrometry analysis, used to quantify changes in the brain proteome, revealed that MGO mainly increase glutamatergic-associated proteins in the midbrain (NMDA, AMPA, glutaminase, VGLUT and EAAT1), but not in the prefrontal cortex, where it mainly affects the electron transport chain. The glycated proteins in the midbrain of MGO-injected Thy1-aSyn mice strongly correlate with PD and dopaminergic pathways. Overall, we demonstrated that MGO-induced glycation accelerates PD-like sensorimotor and cognitive alterations and suggest that the increase of glutamatergic signaling may underly these events. Our study sheds new light into the enhanced vulnerability of the midbrain in PD-related synaptic dysfunction and suggests that glycation suppressors and anti-glutamatergic drugs may hold promise as disease-modifying therapies for synucleinopathies.<\/jats:p>","DOI":"10.1038\/s41531-022-00314-x","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T10:04:33Z","timestamp":1650881073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Glycation modulates glutamatergic signaling and exacerbates Parkinson\u2019s disease-like phenotypes"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2304-4121","authenticated-orcid":false,"given":"Ana","family":"Cheg\u00e3o","sequence":"first","affiliation":[]},{"given":"Mariana","family":"Guarda","sequence":"additional","affiliation":[]},{"given":"Bruno M.","family":"Alexandre","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-0017","authenticated-orcid":false,"given":"Liana","family":"Shvachiy","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Temido-Ferreira","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Marques-Morgado","sequence":"additional","affiliation":[]},{"given":"B\u00e1rbara","family":"Fernandes Gomes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-2616","authenticated-orcid":false,"given":"Rune","family":"Matthiesen","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa V.","family":"Lopes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-7036","authenticated-orcid":false,"given":"Pedro R.","family":"Florindo","sequence":"additional","affiliation":[]},{"given":"Ricardo A.","family":"Gomes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-6785","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Gomes-Alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-6197","authenticated-orcid":false,"given":"Joana E.","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-9259","authenticated-orcid":false,"given":"Hugo","family":"Vicente Miranda","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"314_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"314_CR2","doi-asserted-by":"publisher","first-page":"13709","DOI":"10.1021\/bi961799n","volume":"35","author":"PH Weinreb","year":"1996","unstructured":"Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T. Jr. NACP, a protein implicated in Alzheimer\u2019s disease and learning, is natively unfolded. Biochemistry 35, 13709\u201313715 (1996).","journal-title":"Biochemistry"},{"key":"314_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","volume":"10","author":"K Vekrellis","year":"2011","unstructured":"Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H. J. & Stefanis, L. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol. 10, 1015\u20131025 (2011).","journal-title":"Lancet Neurol."},{"key":"314_CR4","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S1353-8020(11)70010-4","volume":"18","author":"A Puschmann","year":"2012","unstructured":"Puschmann, A., Bhidayasiri, R. & Weiner, W. J. Synucleinopathies from bench to bedside. Parkinsonism Relat. Disord. 18, S24\u2013S27 (2012).","journal-title":"Parkinsonism Relat. Disord."},{"key":"314_CR5","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","volume":"7","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Jakes, R. & Spillantini, M. G. The synucleinopathies: twenty years on. J. Parkinsons Dis. 7, S51\u2013s69 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"314_CR6","doi-asserted-by":"crossref","unstructured":"Dickson, D. W. Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med. 2, a009258 (2012).","DOI":"10.1101\/cshperspect.a009258"},{"key":"314_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/WCO.0000000000000112","volume":"27","author":"JG Goldman","year":"2014","unstructured":"Goldman, J. G. & Postuma, R. Premotor and nonmotor features of Parkinson\u2019s disease. Curr. Opin. Neurol. 27, 434\u2013441 (2014).","journal-title":"Curr. Opin. Neurol."},{"key":"314_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir, S. The clinical symptoms of Parkinson\u2019s disease. J. Neurochem. 139, 318\u2013324 (2016).","journal-title":"J. Neurochem."},{"key":"314_CR9","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer, R. F. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22, S119\u2013S122 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"314_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. Nat. Rev. Neurosci. 18, 435\u2013450 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"314_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14175-5","volume":"7","author":"H Vicente Miranda","year":"2017","unstructured":"Vicente Miranda, H. et al. Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson\u2019s disease. Sci. Rep. 7, 13713 (2017).","journal-title":"Sci. Rep."},{"key":"314_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","volume":"14","author":"A Iwai","year":"1995","unstructured":"Iwai, A. et al. The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467\u2013475 (1995).","journal-title":"Neuron"},{"key":"314_CR13","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","volume":"8","author":"L Maroteaux","year":"1988","unstructured":"Maroteaux, L., Campanelli, J. T. & Scheller, R. H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804\u20132815 (1988).","journal-title":"J. Neurosci."},{"key":"314_CR14","doi-asserted-by":"crossref","unstructured":"McLean, P. J., Ribich, S. & Hyman, B. T. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J. Neural Transm. Suppl. 53\u201363 (2000).","DOI":"10.1007\/978-3-7091-6284-2_5"},{"key":"314_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrn1007","volume":"4","author":"C Soto","year":"2003","unstructured":"Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49\u201360 (2003).","journal-title":"Nat. Rev. Neurosci."},{"key":"314_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","volume":"183","author":"A Oueslati","year":"2010","unstructured":"Oueslati, A., Fournier, M. & Lashuel, H. A. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson\u2019s disease pathogenesis and therapies. Prog. Brain Res. 183, 115\u2013145 (2010).","journal-title":"Prog. Brain Res."},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1471-4159.2007.04764.x","volume":"103","author":"VN Uversky","year":"2007","unstructured":"Uversky, V. N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 103, 17\u201337 (2007).","journal-title":"J. Neurochem."},{"key":"314_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(98)00504-7","volume":"251","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G. et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson\u2019s disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205\u2013208 (1998).","journal-title":"Neurosci. Lett."},{"key":"314_CR19","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"314_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet (Lond., Engl.) 386, 896\u2013912 (2015).","journal-title":"Lancet (Lond., Engl.)"},{"key":"314_CR21","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"314_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"314_CR23","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson, D. W. et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150\u20131157 (2009).","journal-title":"Lancet Neurol."},{"key":"314_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain 122, 1437\u20131448 (1999).","journal-title":"Brain"},{"key":"314_CR25","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley, J. M. & Lees, A. J. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114, 2283\u20132301 (1991).","journal-title":"Brain"},{"key":"314_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fnagi.2014.00087","volume":"6","author":"A Benazzouz","year":"2014","unstructured":"Benazzouz, A., Mamad, O., Abedi, P., Bouali-Benazzouz, R. & Chetrit, J. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson\u2019s disease. Front. Aging Neurosci. 6, 87 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"314_CR27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","volume":"17","author":"P Calabresi","year":"2014","unstructured":"Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V. & Di Filippo, M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat. Neurosci. 17, 1022\u20131030 (2014).","journal-title":"Nat. Neurosci."},{"key":"314_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","volume":"96","author":"V Sgambato-Faure","year":"2012","unstructured":"Sgambato-Faure, V. & Cenci, M. A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson\u2019s disease. Prog. Neurobiol. 96, 69\u201386 (2012).","journal-title":"Prog. Neurobiol."},{"key":"314_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nbd.2014.10.016","volume":"74","author":"ST Masoud","year":"2015","unstructured":"Masoud, S. T. et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol. Dis. 74, 66\u201375 (2015).","journal-title":"Neurobiol. Dis."},{"key":"314_CR30","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","volume":"8","author":"MC Rodriguez-Oroz","year":"2009","unstructured":"Rodriguez-Oroz, M. C. et al. Initial clinical manifestations of Parkinson\u2019s disease: features and pathophysiological mechanisms. Lancet Neurol. 8, 1128\u20131139 (2009).","journal-title":"Lancet Neurol."},{"key":"314_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","volume":"20","author":"H Bernheimer","year":"1973","unstructured":"Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415\u2013455 (1973).","journal-title":"J. Neurol. Sci."},{"key":"314_CR32","first-page":"53","volume":"60","author":"T Wichmann","year":"1993","unstructured":"Wichmann, T. & DeLong, M. R. Pathophysiology of parkinsonian motor abnormalities. Adv. Neurol. 60, 53\u201361 (1993).","journal-title":"Adv. Neurol."},{"key":"314_CR33","first-page":"S7","volume":"44","author":"JT Greenamyre","year":"1994","unstructured":"Greenamyre, J. T. & Porter, R. H. Anatomy and physiology of glutamate in the CNS. Neurology 44, S7\u2013S13 (1994).","journal-title":"Neurology"},{"key":"314_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep30615","volume":"6","author":"DH Root","year":"2016","unstructured":"Root, D. H. et al. Glutamate neurons are intermixed with midbrain dopamine neurons in nonhuman primates and humans. Sci. Rep. 6, 30615 (2016).","journal-title":"Sci. Rep."},{"key":"314_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1472-8206.1998.tb00918.x","volume":"12","author":"F Blandini","year":"1998","unstructured":"Blandini, F. & Greenamyre, J. T. Prospects of glutamate antagonists in the therapy of Parkinson\u2019s disease. Fundam. Clin. Pharm. 12, 4\u201312 (1998).","journal-title":"Fundam. Clin. Pharm."},{"key":"314_CR36","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1002\/ana.410440726","volume":"44","author":"MC Rodriguez","year":"1998","unstructured":"Rodriguez, M. C., Obeso, J. A. & Olanow, C. W. Subthalamic nucleus-mediated excitotoxicity in Parkinson\u2019s disease: a target for neuroprotection. Ann. Neurol. 44, S175\u2013S188 (1998).","journal-title":"Ann. Neurol."},{"key":"314_CR37","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1046\/j.1460-9568.1999.00627.x","volume":"11","author":"E Bezard","year":"1999","unstructured":"Bezard, E., Boraud, T., Bioulac, B. & Gross, C. E. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11, 2167\u20132170 (1999).","journal-title":"Eur. J. Neurosci."},{"key":"314_CR38","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1093\/cercor\/bhp317","volume":"20","author":"BG Garcia","year":"2010","unstructured":"Garcia, B. G., Neely, M. D. & Deutch, A. Y. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cereb. Cortex 20, 2423\u20132432 (2010).","journal-title":"Cereb. Cortex"},{"key":"314_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.expneurol.2009.09.027","volume":"220","author":"WM Caudle","year":"2009","unstructured":"Caudle, W. M. & Zhang, J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp. Neurol. 220, 230\u2013233 (2009).","journal-title":"Exp. Neurol."},{"key":"314_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/0166-2236(89)90074-X","volume":"12","author":"RL Albin","year":"1989","unstructured":"Albin, R. L., Young, A. B. & Penney, J. B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366\u2013375 (1989).","journal-title":"Trends Neurosci."},{"key":"314_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","volume":"3","author":"P Carrillo-Mora","year":"2013","unstructured":"Carrillo-Mora, P., Silva-Adaya, D. & Villase\u00f1or-Aguayo, K. Glutamate in Parkinson\u2019s disease: role of antiglutamatergic drugs. Basal Ganglia 3, 147\u2013157 (2013).","journal-title":"Basal Ganglia"},{"key":"314_CR42","doi-asserted-by":"publisher","first-page":"e5921","DOI":"10.1097\/MD.0000000000005921","volume":"96","author":"YW Yang","year":"2017","unstructured":"Yang, Y. W. et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96, e5921 (2017).","journal-title":"Medicine (Baltimore)"},{"key":"314_CR43","doi-asserted-by":"publisher","first-page":"842","DOI":"10.2337\/dc06-2011","volume":"30","author":"G Hu","year":"2007","unstructured":"Hu, G., Jousilahti, P., Bidel, S., Antikainen, R. & Tuomilehto, J. Type 2 diabetes and the risk of Parkinson\u2019s disease. Diabetes Care 30, 842\u2013847 (2007).","journal-title":"Diabetes Care"},{"key":"314_CR44","doi-asserted-by":"publisher","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","volume":"90","author":"G Pagano","year":"2018","unstructured":"Pagano, G. et al. Diabetes mellitus and Parkinson disease. Neurology 90, e1654\u2013e1662 (2018).","journal-title":"Neurology"},{"key":"314_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145-146","author":"D Athauda","year":"2016","unstructured":"Athauda, D. & Foltynie, T. Insulin resistance and Parkinson\u2019s disease: a new target for disease modification? Prog. Neurobiol. 145-146, 98\u2013120 (2016).","journal-title":"Prog. Neurobiol."},{"key":"314_CR46","doi-asserted-by":"publisher","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","volume":"95","author":"X Yue","year":"2016","unstructured":"Yue, X. et al. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine (Baltimore) 95, e3549 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"314_CR47","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1089\/ars.2009.2484","volume":"11","author":"A Negre-Salvayre","year":"2009","unstructured":"Negre-Salvayre, A., Salvayre, R., Auge, N., Pamplona, R. & Portero-Otin, M. Hyperglycemia and glycation in diabetic complications. Antioxid. Redox Signal. 11, 3071\u20133109 (2009).","journal-title":"Antioxid. Redox Signal."},{"key":"314_CR48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1042\/CS20140683","volume":"128","author":"DE Maessen","year":"2015","unstructured":"Maessen, D. E., Stehouwer, C. D. & Schalkwijk, C. G. The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases. Clin. Sci. (Lond.) 128, 839\u2013861 (2015).","journal-title":"Clin. Sci. (Lond.)"},{"key":"314_CR49","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/mds.26566","volume":"31","author":"H Vicente Miranda","year":"2016","unstructured":"Vicente Miranda, H., El-Agnaf, O. M. & Outeiro, T. F. Glycation in Parkinson\u2019s disease and Alzheimer\u2019s disease. Mov. Disord. 31, 782\u2013790 (2016).","journal-title":"Mov. Disord."},{"key":"314_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/path.2682","volume":"221","author":"H Vicente Miranda","year":"2010","unstructured":"Vicente Miranda, H. & Outeiro, T. F. The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol. 221, 13\u201325 (2010).","journal-title":"J. Pathol."},{"key":"314_CR51","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00726-010-0777-y","volume":"42","author":"G Munch","year":"2012","unstructured":"Munch, G., Westcott, B., Menini, T. & Gugliucci, A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids 42, 1221\u20131236 (2012).","journal-title":"Amino Acids"},{"key":"314_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/1753-0407.12160","volume":"6","author":"X Kong","year":"2014","unstructured":"Kong, X. et al. Increased plasma levels of the methylglyoxal in patients with newly diagnosed type 2 diabetes 2. J. Diabetes 6, 535\u2013540 (2014).","journal-title":"J. Diabetes"},{"key":"314_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.clinbiochem.2010.11.004","volume":"44","author":"J Lu","year":"2011","unstructured":"Lu, J. et al. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin. Biochem 44, 307\u2013311 (2011).","journal-title":"Clin. Biochem"},{"key":"314_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.chroma.2017.06.041","volume":"1509","author":"M Pastor-Belda","year":"2017","unstructured":"Pastor-Belda, M. et al. Glyoxal and methylglyoxal as urinary markers of diabetes. Determination using a dispersive liquid-liquid microextraction procedure combined with gas chromatography-mass spectrometry. J. Chromatogr. A 1509, 43\u201349 (2017).","journal-title":"J. Chromatogr. A"},{"key":"314_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10157-014-1018-6","volume":"19","author":"M Senda","year":"2015","unstructured":"Senda, M. et al. The strong relation between post-hemodialysis blood methylglyoxal levels and post-hemodialysis blood glucose concentration rise. Clin. Exp. Nephrol. 19, 527\u2013533 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"314_CR56","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/brain\/awx056","volume":"140","author":"H Vicente Miranda","year":"2017","unstructured":"Vicente Miranda, H. et al. Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain 140, 1399\u20131419 (2017).","journal-title":"Brain"},{"key":"314_CR57","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1096\/fj.201902936R","volume":"34","author":"H Vicente Miranda","year":"2020","unstructured":"Vicente Miranda, H. et al. Hsp27 reduces glycation-induced toxicity and aggregation of alpha-synuclein. FASEB J. 34, 6718\u20136728 (2020).","journal-title":"FASEB J."},{"key":"314_CR58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet, M. F. et al. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (\u201cLine 61\u201d) mice. Neurotherapeutics 9, 297\u2013314 (2012).","journal-title":"Neurotherapeutics"},{"key":"314_CR59","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jnr.10231","volume":"68","author":"E Rockenstein","year":"2002","unstructured":"Rockenstein, E. et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568\u2013578 (2002).","journal-title":"J. Neurosci. Res."},{"key":"314_CR60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrn2652","volume":"10","author":"SP Brooks","year":"2009","unstructured":"Brooks, S. P. & Dunnett, S. B. Tests to assess motor phenotype in mice: a user\u2019s guide. Nat. Rev. Neurosci. 10, 519\u2013529 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"314_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnins.2016.00033","volume":"10","author":"JW Zhu","year":"2016","unstructured":"Zhu, J. W., Li, Y. F., Wang, Z. T., Jia, W. Q. & Xu, R. X. Toll-like receptor 4 deficiency impairs motor coordination. Front. Neurosci. 10, 33 (2016).","journal-title":"Front. Neurosci."},{"key":"314_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","volume":"73","author":"K Matsuura","year":"1997","unstructured":"Matsuura, K., Kabuto, H., Makino, H. & Ogawa, N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 73, 45\u201348 (1997).","journal-title":"J. Neurosci. Methods"},{"key":"314_CR63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jps.3030460322","volume":"46","author":"NW Dunham","year":"1957","unstructured":"Dunham, N. W. & Miya, T. S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. Am. Pharm. Assoc. 46, 208\u2013209 (1957).","journal-title":"J. Am. Pharm. Assoc. Am. Pharm. Assoc."},{"key":"314_CR64","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/hmg\/ddg249","volume":"12","author":"D Glynn","year":"2003","unstructured":"Glynn, D., Bortnick, R. A. & Morton, A. J. Complexin II is essential for normal neurological function in mice. Hum. Mol. Genet. 12, 2431\u20132448 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"314_CR65","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/nprot.2009.125","volume":"4","author":"V Bouet","year":"2009","unstructured":"Bouet, V. et al. The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat. Protoc. 4, 1560\u20131564 (2009).","journal-title":"Nat. Protoc."},{"key":"314_CR66","doi-asserted-by":"crossref","unstructured":"Guyenet, S. J. et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J. Vis. Exp. 1787 (2010).","DOI":"10.3791\/1787"},{"key":"314_CR67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4939-8994-2_10","volume":"1916","author":"AK Kraeuter","year":"2019","unstructured":"Kraeuter, A. K., Guest, P. C. & Sarnyai, Z. The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol. Biol. (Clifton, N. J.) 1916, 105\u2013111 (2019).","journal-title":"Methods Mol. Biol. (Clifton, N. J.)"},{"key":"314_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0149-7634(01)00041-0","volume":"26","author":"R Lalonde","year":"2002","unstructured":"Lalonde, R. The neurobiological basis of spontaneous alternation. Neurosci. Biobehav. Rev. 26, 91\u2013104 (2002).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"314_CR69","doi-asserted-by":"crossref","unstructured":"Komada, M., Takao, K. & Miyakawa, T. Elevated plus maze for mice. J. Vis. Exp. 1088 (2008).","DOI":"10.3791\/1088"},{"key":"314_CR70","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nprot.2007.44","volume":"2","author":"AA Walf","year":"2007","unstructured":"Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2, 322\u2013328 (2007).","journal-title":"Nat. Protoc."},{"key":"314_CR71","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1460-9568.2008.06346.x","volume":"28","author":"SM Fleming","year":"2008","unstructured":"Fleming, S. M. et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 28, 247\u2013256 (2008).","journal-title":"Eur. J. Neurosci."},{"key":"314_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2010.03.004","volume":"211","author":"TN Taylor","year":"2010","unstructured":"Taylor, T. N., Greene, J. G. & Miller, G. W. Behavioral phenotyping of mouse models of Parkinson\u2019s disease. Behavioural Brain Res. 211, 1\u201310 (2010).","journal-title":"Behavioural Brain Res."},{"key":"314_CR73","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","volume":"134","author":"K Kalinderi","year":"2016","unstructured":"Kalinderi, K., Bostantjopoulou, S. & Fidani, L. The genetic background of Parkinson\u2019s disease: current progress and future prospects. Acta Neurol. Scand. 134, 314\u2013326 (2016).","journal-title":"Acta Neurol. Scand."},{"key":"314_CR74","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","volume":"18","author":"S Lesage","year":"2009","unstructured":"Lesage, S. & Brice, A. Parkinson\u2019s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48\u2013R59 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"314_CR75","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes, O. B. & Storstein, A. Epidemiology of Parkinson\u2019s disease. J. Neural Transm. (Vienna) 124, 901\u2013905 (2017).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"314_CR76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"A Elbaz","year":"2016","unstructured":"Elbaz, A., Carcaillon, L., Kab, S. & Moisan, F. Epidemiology of Parkinson\u2019s disease. Rev. Neurologique 172, 14\u201326 (2016).","journal-title":"Rev. Neurologique"},{"key":"314_CR77","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","volume":"1","author":"RA DeFronzo","year":"2015","unstructured":"DeFronzo, R. A. et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Prim. 1, 15019 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"314_CR78","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5777","volume":"255","author":"L Sousa","year":"2021","unstructured":"Sousa, L., Guarda, M., Meneses, M. J., Macedo, M. P. & Vicente Miranda, H. Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases. J. Pathol. 255, 346\u2013361 (2021).","journal-title":"J. Pathol."},{"key":"314_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep36798","volume":"6","author":"H Vicente Miranda","year":"2016","unstructured":"Vicente Miranda, H. et al. Glycation potentiates neurodegeneration in models of Huntington\u2019s disease. Sci. Rep. 6, 36798 (2016).","journal-title":"Sci. Rep."},{"key":"314_CR80","doi-asserted-by":"publisher","first-page":"238485","DOI":"10.1155\/2014\/238485","volume":"2014","author":"C Angeloni","year":"2014","unstructured":"Angeloni, C., Zambonin, L. & Hrelia, S. Role of methylglyoxal in Alzheimer\u2019s disease. Biomed. Res. Int. 2014, 238485 (2014).","journal-title":"Biomed. Res. Int."},{"key":"314_CR81","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/acschemneuro.7b00410","volume":"9","author":"K Batkulwar","year":"2018","unstructured":"Batkulwar, K. et al. Advanced glycation end products modulate amyloidogenic APP processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer\u2019s disease. ACS Chem. Neurosci. 9, 988\u20131000 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"314_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.180","volume":"4","author":"XH Li","year":"2013","unstructured":"Li, X. H. et al. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis. 4, e673 (2013).","journal-title":"Cell Death Dis."},{"key":"314_CR83","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jneumeth.2014.06.006","volume":"233","author":"A Kuo","year":"2014","unstructured":"Kuo, A. & Smith, M. T. Theoretical and practical applications of the intracerebroventricular route for CSF sampling and drug administration in CNS drug discovery research: a mini review. J. Neurosci. Methods 233, 166\u2013171 (2014).","journal-title":"J. Neurosci. Methods"},{"key":"314_CR84","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/hmg\/ddp333","volume":"18","author":"VB Mattis","year":"2009","unstructured":"Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C. W. & Lorson, C. L. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet. 18, 3906\u20133913 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"314_CR85","first-page":"225","volume":"246","author":"MA Passini","year":"2004","unstructured":"Passini, M. A., Watson, D. J. & Wolfe, J. H. Gene delivery to the mouse brain with adeno-associated virus. Methods Mol. Biol. (Clifton, N. J.) 246, 225\u2013236 (2004).","journal-title":"Methods Mol. Biol. (Clifton, N. J.)"},{"key":"314_CR86","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.1128\/JVI.75.24.12382-12392.2001","volume":"75","author":"MA Passini","year":"2001","unstructured":"Passini, M. A. & Wolfe, J. H. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J. Virol. 75, 12382\u201312392 (2001).","journal-title":"J. Virol."},{"key":"314_CR87","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1471-4159.2010.06693.x","volume":"113","author":"B Hambsch","year":"2010","unstructured":"Hambsch, B. et al. Methylglyoxal-mediated anxiolysis involves increased protein modification and elevated expression of glyoxalase 1 in the brain. J. Neurochem. 113, 1240\u20131251 (2010).","journal-title":"J. Neurochem."},{"key":"314_CR88","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1172\/JCI61319","volume":"122","author":"MG Distler","year":"2012","unstructured":"Distler, M. G. et al. Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal. J. Clin. Investig. 122, 2306\u20132315 (2012).","journal-title":"J. Clin. Investig."},{"key":"314_CR89","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.physbeh.2016.05.046","volume":"164","author":"F Hansen","year":"2016","unstructured":"Hansen, F. et al. Methylglyoxal can mediate behavioral and neurochemical alterations in rat brain. Physiol. Behav. 164, 93\u2013101 (2016).","journal-title":"Physiol. Behav."},{"key":"314_CR90","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1177\/0269881113495596","volume":"27","author":"V Jakubcakova","year":"2013","unstructured":"Jakubcakova, V. et al. The glycolytic metabolite methylglyoxal induces changes in vigilance by generating low-amplitude non-REM sleep. J. Psychopharmacol. (Oxf., Engl.) 27, 1070\u20131075 (2013).","journal-title":"J. Psychopharmacol. (Oxf., Engl.)"},{"key":"314_CR91","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/nn.4648","volume":"20","author":"DG Ferreira","year":"2017","unstructured":"Ferreira, D. G. et al. alpha-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat. Neurosci. 20, 1569\u20131579 (2017).","journal-title":"Nat. Neurosci."},{"key":"314_CR92","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1523\/JNEUROSCI.3080-04.2004","volume":"24","author":"SM Fleming","year":"2004","unstructured":"Fleming, S. M. et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 24, 9434\u20139440 (2004).","journal-title":"J. Neurosci."},{"key":"314_CR93","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","volume":"20","author":"H van der Putten","year":"2000","unstructured":"van der Putten, H. et al. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021\u20136029 (2000).","journal-title":"J. Neurosci."},{"key":"314_CR94","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/j.1460-9568.2012.08012.x","volume":"35","author":"I Magen","year":"2012","unstructured":"Magen, I. et al. Cognitive deficits in a mouse model of pre-manifest Parkinson\u2019s disease. Eur. J. Neurosci. 35, 870\u2013882 (2012).","journal-title":"Eur. J. Neurosci."},{"key":"314_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.16062","volume":"10","author":"K Takakusaki","year":"2017","unstructured":"Takakusaki, K. Functional neuroanatomy for posture and gait control. J. Mov. Disord. 10, 1\u201317 (2017).","journal-title":"J. Mov. Disord."},{"key":"314_CR96","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000480748","volume":"33","author":"AC Bostan","year":"2018","unstructured":"Bostan, A. C., Dum, R. P. & Strick, P. L. Functional anatomy of basal ganglia circuits with the cerebral cortex and the cerebellum. Prog. Neurol. Surg. 33, 50\u201361 (2018).","journal-title":"Prog. Neurol. Surg."},{"key":"314_CR97","doi-asserted-by":"publisher","first-page":"a009621","DOI":"10.1101\/cshperspect.a009621","volume":"2","author":"JL Lanciego","year":"2012","unstructured":"Lanciego, J. L., Luquin, N. & Obeso, J. A. Functional neuroanatomy of the basal ganglia. Cold Spring Harb. Perspect. Med. 2, a009621 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"314_CR98","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0924-977X(99)00067-X","volume":"10","author":"M Kamata","year":"2000","unstructured":"Kamata, M., Higuchi, H., Yoshimoto, M., Yoshida, K. & Shimizu, T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur. Neuropsychopharmacol. 10, 129\u2013132 (2000).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"314_CR99","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JPD-171285","volume":"8","author":"A Konig","year":"2018","unstructured":"Konig, A., Vicente Miranda, H. & Outeiro, T. F. Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson\u2019s disease. J. Parkinson\u2019s Dis. 8, 33\u201343 (2018).","journal-title":"J. Parkinson\u2019s Dis."},{"key":"314_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44358-1","volume":"9","author":"Z Irshad","year":"2019","unstructured":"Irshad, Z. et al. Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal. Sci. Rep. 9, 7889 (2019).","journal-title":"Sci. Rep."},{"key":"314_CR101","doi-asserted-by":"publisher","first-page":"18338","DOI":"10.1523\/JNEUROSCI.1249-11.2011","volume":"31","author":"M Belanger","year":"2011","unstructured":"Belanger, M. et al. Role of the glyoxalase system in astrocyte-mediated neuroprotection. J. Neurosci. 31, 18338\u201318352 (2011).","journal-title":"J. Neurosci."},{"key":"314_CR102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fnins.2015.00023","volume":"9","author":"I Allaman","year":"2015","unstructured":"Allaman, I., Belanger, M. & Magistretti, P. J. Methylglyoxal, the dark side of glycolysis. Front. Neurosci. 9, 23 (2015).","journal-title":"Front. Neurosci."},{"key":"314_CR103","doi-asserted-by":"publisher","first-page":"843505","DOI":"10.1155\/2012\/843505","volume":"2012","author":"PB Pun","year":"2012","unstructured":"Pun, P. B. & Murphy, M. P. Pathological significance of mitochondrial glycation. Int J. Cell Biol. 2012, 843505 (2012).","journal-title":"Int J. Cell Biol."},{"key":"314_CR104","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neurobiolaging.2006.05.007","volume":"28","author":"SG de Arriba","year":"2007","unstructured":"de Arriba, S. G. et al. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells\u2013protection by carbonyl scavengers. Neurobiol. Aging 28, 1044\u20131050 (2007).","journal-title":"Neurobiol. Aging"},{"key":"314_CR105","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.bcp.2004.06.013","volume":"68","author":"N Shangari","year":"2004","unstructured":"Shangari, N. & O\u2019Brien, P. J. The cytotoxic mechanism of glyoxal involves oxidative stress. Biochem Pharm. 68, 1433\u20131442 (2004).","journal-title":"Biochem Pharm."},{"key":"314_CR106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/jnc.13731","volume":"139","author":"A Bose","year":"2016","unstructured":"Bose, A. & Beal, M. F. Mitochondrial dysfunction in Parkinson\u2019s disease. J. Neurochem. 139, 216\u2013231 (2016).","journal-title":"J. Neurochem."},{"key":"314_CR107","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","volume":"42","author":"M Nguyen","year":"2019","unstructured":"Nguyen, M., Wong, Y. C., Ysselstein, D., Severino, A. & Krainc, D. Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson\u2019s disease. Trends Neurosci. 42, 140\u2013149 (2019).","journal-title":"Trends Neurosci."},{"key":"314_CR108","doi-asserted-by":"publisher","first-page":"107559","DOI":"10.1016\/j.neuropharm.2019.03.002","volume":"161","author":"E Pajarillo","year":"2019","unstructured":"Pajarillo, E., Rizor, A., Lee, J., Aschner, M. & Lee, E. The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: potential targets for neurotherapeutics. Neuropharmacology 161, 107559 (2019).","journal-title":"Neuropharmacology"},{"key":"314_CR109","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41537-017-0037-1","volume":"3","author":"SM O\u2019Donovan","year":"2017","unstructured":"O\u2019Donovan, S. M., Sullivan, C. R. & McCullumsmith, R. E. The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders. NPJ Schizophr. 3, 32 (2017).","journal-title":"NPJ Schizophr."},{"key":"314_CR110","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.molmed.2010.12.008","volume":"17","author":"TW Lai","year":"2011","unstructured":"Lai, T. W., Shyu, W. C. & Wang, Y. T. Stroke intervention pathways: NMDA receptors and beyond. Trends Mol. Med. 17, 266\u2013275 (2011).","journal-title":"Trends Mol. Med."},{"key":"314_CR111","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","volume":"82","author":"MP Parsons","year":"2014","unstructured":"Parsons, M. P. & Raymond, L. A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82, 279\u2013293 (2014).","journal-title":"Neuron"},{"key":"314_CR112","doi-asserted-by":"publisher","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","volume":"32","author":"MJ Diogenes","year":"2012","unstructured":"Diogenes, M. J. et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750\u201311762 (2012).","journal-title":"J. Neurosci."},{"key":"314_CR113","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.biopha.2018.08.062","volume":"107","author":"XS Wang","year":"2018","unstructured":"Wang, X. S. et al. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson\u2019s rats. Biomed. Pharmacother. 107, 769\u2013776 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"314_CR114","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1523\/JNEUROSCI.1871-20.2020","volume":"41","author":"D Trudler","year":"2021","unstructured":"Trudler, D. et al. alpha-Synuclein oligomers induce glutamate release from astrocytes and excessive extrasynaptic NMDAR activity in neurons, thus contributing to synapse loss. J. Neurosci. 41, 2264\u20132273 (2021).","journal-title":"J. Neurosci."},{"key":"314_CR115","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino, L., Tremblay, M. E. & Civiero, L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J. Pharm. Sci. 144, 151\u2013164 (2020).","journal-title":"J. Pharm. Sci."},{"key":"314_CR116","doi-asserted-by":"publisher","first-page":"e84081","DOI":"10.1371\/journal.pone.0084081","volume":"9","author":"A Gr\u00f6ger","year":"2014","unstructured":"Gr\u00f6ger, A., Kolb, R., Sch\u00e4fer, R. & Klose, U. Dopamine reduction in the substantia nigra of Parkinson\u2019s disease patients confirmed by in vivo magnetic resonance spectroscopic imaging. PLoS One 9, e84081 (2014).","journal-title":"PLoS One"},{"key":"314_CR117","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neubiorev.2015.09.007","volume":"59","author":"CP Weingarten","year":"2015","unstructured":"Weingarten, C. P., Sundman, M. H., Hickey, P. & Chen, N. K. Neuroimaging of Parkinson\u2019s disease: expanding views. Neurosci. Biobehav. Rev. 59, 16\u201352 (2015).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"314_CR118","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3389\/fneur.2018.00806","volume":"9","author":"RL O\u2019Gorman Tuura","year":"2018","unstructured":"O\u2019Gorman Tuura, R. L., Baumann, C. R. & Baumann-Vogel, H. Beyond dopamine: GABA, glutamate, and the axial symptoms of Parkinson disease. Front Neurol. 9, 806 (2018).","journal-title":"Front Neurol."},{"key":"314_CR119","doi-asserted-by":"publisher","first-page":"e0191670","DOI":"10.1371\/journal.pone.0191670","volume":"13","author":"M Figura","year":"2018","unstructured":"Figura, M. et al. Serum amino acid profile in patients with Parkinson\u2019s disease. PLoS One 13, e0191670 (2018).","journal-title":"PLoS One"},{"key":"314_CR120","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0304-3940(92)90015-Y","volume":"145","author":"Y Iwasaki","year":"1992","unstructured":"Iwasaki, Y., Ikeda, K., Shiojima, T. & Kinoshita, M. Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson\u2019s disease. Neurosci. Lett. 145, 175\u2013177 (1992).","journal-title":"Neurosci. Lett."},{"key":"314_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","volume":"3","author":"P Carrillo-Mora","year":"2013","unstructured":"Carrillo-Mora, P., Silva-Adaya, D. & Villase\u00f1or-Aguayo, K. Glutamate in Parkinson\u2019s disease: role of antiglutamatergic drugs. Basal Ganglia 3, 147\u2013157 (2013).","journal-title":"Basal Ganglia"},{"key":"314_CR122","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1042\/BST20140006","volume":"42","author":"MA Cenci","year":"2014","unstructured":"Cenci, M. A. Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson\u2019s disease. Biochem Soc. Trans. 42, 600\u2013604 (2014).","journal-title":"Biochem Soc. Trans."},{"key":"314_CR123","doi-asserted-by":"publisher","first-page":"Ii36","DOI":"10.1007\/PL00007759","volume":"247","author":"TN Chase","year":"2000","unstructured":"Chase, T. N., Oh, J. D. & Konitsiotis, S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247, Ii36\u2013Ii42 (2000).","journal-title":"J. Neurol."},{"key":"314_CR124","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11010-011-0773-x","volume":"353","author":"MS Nandhu","year":"2011","unstructured":"Nandhu, M. S. et al. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson\u2019s rat: functional recovery with bone marrow cells, serotonin and GABA. Mol. Cell Biochem. 353, 47\u201357 (2011).","journal-title":"Mol. Cell Biochem."},{"key":"314_CR125","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/BF02682089","volume":"130","author":"VG Kucheryanu","year":"2000","unstructured":"Kucheryanu, V. G. & Kryzhanovskii, G. N. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull. Exp. Biol. Med. 130, 629\u2013632 (2000).","journal-title":"Bull. Exp. Biol. Med."},{"key":"314_CR126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11064-012-0889-8","volume":"38","author":"X Qu","year":"2013","unstructured":"Qu, X. et al. Hippocampal glutamate level and glutamate aspartate transporter (GLAST) are up-regulated in senior rat associated with isoflurane-induced spatial learning\/memory impairment. Neurochem. Res. 38, 59\u201373 (2013).","journal-title":"Neurochem. Res."},{"key":"314_CR127","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1101\/lm.023259.111","volume":"19","author":"JD Pita-Almenar","year":"2012","unstructured":"Pita-Almenar, J. D., Zou, S., Colbert, C. M. & Eskin, A. Relationship between increase in astrocytic GLT-1 glutamate transport and late-LTP. Learn Mem. 19, 615\u2013626 (2012).","journal-title":"Learn Mem."},{"key":"314_CR128","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.mehy.2012.02.009","volume":"78","author":"DJ McCarthy","year":"2012","unstructured":"McCarthy, D. J. et al. Glutamate-based depression GBD. Med. Hypotheses 78, 675\u2013681 (2012).","journal-title":"Med. Hypotheses"},{"key":"314_CR129","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","volume":"89","author":"C Vilarino-Guell","year":"2011","unstructured":"Vilarino-Guell, C. et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet 89, 162\u2013167 (2011).","journal-title":"Am. J. Hum. Genet"},{"key":"314_CR130","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","volume":"89","author":"A Zimprich","year":"2011","unstructured":"Zimprich, A. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet 89, 168\u2013175 (2011).","journal-title":"Am. J. Hum. Genet"},{"key":"314_CR131","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.celrep.2015.08.001","volume":"12","author":"FL Tang","year":"2015","unstructured":"Tang, F. L. et al. VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep. 12, 1631\u20131643 (2015).","journal-title":"Cell Rep."},{"key":"314_CR132","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3389\/fnmol.2018.00445","volume":"11","author":"G Zalcman","year":"2018","unstructured":"Zalcman, G., Federman, N. & Romano, A. CaMKII isoforms in learning and memory: localization and function. Front Mol. Neurosci. 11, 445 (2018).","journal-title":"Front Mol. Neurosci."},{"key":"314_CR133","doi-asserted-by":"publisher","first-page":"29627","DOI":"10.1074\/jbc.M112.367219","volume":"287","author":"T Steinkellner","year":"2012","unstructured":"Steinkellner, T. et al. Ca(2+)\/calmodulin-dependent protein kinase IIalpha (alphaCaMKII) controls the activity of the dopamine transporter: implications for Angelman syndrome. J. Biol. Chem. 287, 29627\u201329635 (2012).","journal-title":"J. Biol. Chem."},{"key":"314_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/srep06811","volume":"4","author":"S Zhang","year":"2014","unstructured":"Zhang, S., Xie, C., Wang, Q. & Liu, Z. Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson\u2019s rats. Sci. Rep. 4, 6811 (2014).","journal-title":"Sci. Rep."},{"key":"314_CR135","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","volume":"31","author":"KW Lee","year":"2011","unstructured":"Lee, K. W. et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J. Neurosci. 31, 6963\u20136971 (2011).","journal-title":"J. Neurosci."},{"key":"314_CR136","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/acn3.337","volume":"3","author":"HJ Park","year":"2016","unstructured":"Park, H. J. et al. Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann. Clin. Transl. Neurol. 3, 769\u2013780 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"314_CR137","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1111\/j.1742-4658.2005.04872.x","volume":"272","author":"RA Gomes","year":"2005","unstructured":"Gomes, R. A. et al. Protein glycation in Saccharomyces cerevisiae. Argpyrimidine formation and methylglyoxal catabolism. FEBS J. 272, 4521\u20134531 (2005).","journal-title":"FEBS J."},{"key":"314_CR138","doi-asserted-by":"publisher","first-page":"5273","DOI":"10.1111\/j.1742-4658.2006.05520.x","volume":"273","author":"RA Gomes","year":"2006","unstructured":"Gomes, R. A. et al. Yeast protein glycation in vivo by methylglyoxal. Molecular modification of glycolytic enzymes and heat shock proteins. FEBS J. 273, 5273\u20135287 (2006).","journal-title":"FEBS J."},{"key":"314_CR139","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bbrc.2006.10.085","volume":"351","author":"TF Outeiro","year":"2006","unstructured":"Outeiro, T. F. et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem. Biophys. Res. Commun. 351, 631\u2013638 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"314_CR140","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/BST20140010","volume":"42","author":"M Arai","year":"2014","unstructured":"Arai, M., Nihonmatsu-Kikuchi, N., Itokawa, M., Rabbani, N. & Thornalley, P. J. Measurement of glyoxalase activities. Biochem Soc. Trans. 42, 491\u2013494 (2014).","journal-title":"Biochem Soc. Trans."},{"key":"314_CR141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0006-2952(00)00287-2","volume":"60","author":"PJ Thornalley","year":"2000","unstructured":"Thornalley, P. J., Yurek-George, A. & Argirov, O. K. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem. Pharm. 60, 55\u201365 (2000).","journal-title":"Biochem. Pharm."},{"key":"314_CR142","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jnr.22611","volume":"89","author":"HA Lam","year":"2011","unstructured":"Lam, H. A. et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J. Neurosci. Res. 89, 1091\u20131102 (2011).","journal-title":"J. Neurosci. Res."},{"key":"314_CR143","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.neuro.2018.08.001","volume":"69","author":"L Shvachiy","year":"2018","unstructured":"Shvachiy, L., Geraldes, V., Amaro-Leal, A. & Rocha, I. Intermittent low-level lead exposure provokes anxiety, hypertension, autonomic dysfunction and neuroinflammation. Neurotoxicology 69, 307\u2013319 (2018).","journal-title":"Neurotoxicology"},{"key":"314_CR144","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"314_CR145","doi-asserted-by":"publisher","first-page":"e2000374","DOI":"10.1371\/journal.pbio.2000374","volume":"15","author":"RM de Oliveira","year":"2017","unstructured":"de Oliveira, R. M. et al. The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol. 15, e2000374 (2017).","journal-title":"PLoS Biol."},{"key":"314_CR146","unstructured":"Abramoff, M. D., Magelhaes, P. J. & Ram, S. J. Image processing with ImageJ. Biophotonics Int. 11, 36\u201342 (2004)."},{"key":"314_CR147","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanhausser","year":"2011","unstructured":"Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337\u2013342 (2011).","journal-title":"Nature"},{"key":"314_CR148","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","volume":"19","author":"BM Bolstad","year":"2003","unstructured":"Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185\u2013193 (2003).","journal-title":"Bioinformatics"},{"key":"314_CR149","doi-asserted-by":"crossref","unstructured":"Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet Mol. Biol. 3, Article3 (2004).","DOI":"10.2202\/1544-6115.1027"},{"key":"314_CR150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"314_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-015-0611-3","volume":"16","author":"H Heberle","year":"2015","unstructured":"Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. & Minghim, R. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. BMC Bioinforma. 16, 169 (2015).","journal-title":"BMC Bioinforma."},{"key":"314_CR152","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"314_CR153","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie, Z. et al. Gene set knowledge discovery with Enrichr. Curr. Protoc. 1, e90 (2021).","journal-title":"Curr. Protoc."},{"key":"314_CR154","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/nar\/28.18.3442","volume":"28","author":"B Snel","year":"2000","unstructured":"Snel, B., Lehmann, G., Bork, P. & Huynen, M. A. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 28, 3442\u20133444 (2000).","journal-title":"Nucleic Acids Res."},{"key":"314_CR155","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"C von Mering","year":"2003","unstructured":"von Mering, C. et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 31, 258\u2013261 (2003).","journal-title":"Nucleic Acids Res."},{"key":"314_CR156","doi-asserted-by":"publisher","first-page":"D433","DOI":"10.1093\/nar\/gki005","volume":"33","author":"C von Mering","year":"2005","unstructured":"von Mering, C. et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 33, D433\u2013D437 (2005).","journal-title":"Nucleic Acids Res."},{"key":"314_CR157","doi-asserted-by":"publisher","first-page":"D358","DOI":"10.1093\/nar\/gkl825","volume":"35","author":"C von Mering","year":"2007","unstructured":"von Mering, C. et al. STRING 7\u2013recent developments in the integration and prediction of protein interactions. Nucleic Acids Res. 35, D358\u2013D362 (2007).","journal-title":"Nucleic Acids Res."},{"key":"314_CR158","doi-asserted-by":"publisher","first-page":"D412","DOI":"10.1093\/nar\/gkn760","volume":"37","author":"LJ Jensen","year":"2009","unstructured":"Jensen, L. J. et al. STRING 8\u2013a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37, D412\u2013D416 (2009).","journal-title":"Nucleic Acids Res."},{"key":"314_CR159","doi-asserted-by":"publisher","first-page":"D561","DOI":"10.1093\/nar\/gkq973","volume":"39","author":"D Szklarczyk","year":"2011","unstructured":"Szklarczyk, D. et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561\u2013D568 (2011).","journal-title":"Nucleic Acids Res."},{"key":"314_CR160","doi-asserted-by":"publisher","first-page":"D808","DOI":"10.1093\/nar\/gks1094","volume":"41","author":"A Franceschini","year":"2013","unstructured":"Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808\u2013D815 (2013).","journal-title":"Nucleic Acids Res."},{"key":"314_CR161","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/bioinformatics\/btv696","volume":"32","author":"A Franceschini","year":"2016","unstructured":"Franceschini, A., Lin, J., von Mering, C. & Jensen, L. J. SVD-phy: improved prediction of protein functional associations through singular value decomposition of phylogenetic profiles. Bioinformatics 32, 1085\u20131087 (2016).","journal-title":"Bioinformatics"},{"key":"314_CR162","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447\u2013D452 (2015).","journal-title":"Nucleic Acids Res."},{"key":"314_CR163","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","volume":"45","author":"D Szklarczyk","year":"2017","unstructured":"Szklarczyk, D. et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362\u2013d368 (2017).","journal-title":"Nucleic Acids Res."},{"key":"314_CR164","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00314-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00314-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T22:14:39Z","timestamp":1727043279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00314-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00314-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}